首页 > 最新文献

Annales de biologie clinique最新文献

英文 中文
[Evaluation of an algorithm based on quantitative assays of glomerular parameters (albuminuria and urinary IgG) for proteinuria typing]. [基于肾小球参数(白蛋白尿和尿 IgG)定量检测的蛋白尿分型算法评估]。
Pub Date : 2024-06-05 DOI: 10.1684/abc.2024.1887
Ihsane Benlyamani, Nathalie Rousseau, Christine Lombard, Emmanuel Villar, Matthieu Pecquet

The first orientation test for proteinuria typing is electrophoresis. However, this technique has several drawbacks, such as delayed turnaround time and subjective readings. Some laboratories therefore use quantitative assays of glomerular markers combined with tubular markers. However, the cost of reagents and the instability of certain markers are significant drawbacks for some peripheral laboratories. The aim of this study is to evaluate the implementation of an algorithm based on parameters that can be used by all laboratories for proteinuria typing within a timeframe compatible with the urgency of the situation. Albuminuria and urinary IgG were determined on 161 urines. ROC curves were produced, using urine electrophoresis read by an expert center as the reference method. The decision thresholds used are: glomerular proteinuria is defined by a Albumin+IgGproteinsratio greater than 75.4% (100% specificity), and tubular or overload proteinuria is defined by by a Albuminproteinsratio less than 37.3% (100% sensitivity). Agreement between the results of the algorithm selected and the reference method used in our study was 88 %, with a kappa value of 0.807 (95% CI [0.729 to 0.885]). The algorithm's performance suggests that it can find its place in the diagnostic strategy for clinically significant proteinuria, despite its limited indications. It is up to each biologist to assess the value of this algorithm in relation to the recruitment, habits and needs of clinicians.

蛋白尿分型的第一种定向检测方法是电泳。然而,这种技术有几个缺点,如周转时间延迟和读数主观。因此,一些实验室采用肾小球标记物与肾小管标记物相结合的定量检测方法。然而,试剂的成本和某些标记物的不稳定性是一些外围实验室的重大缺陷。本研究的目的是评估一种基于参数的算法的实施情况,这种算法可在符合紧急状况的时限内被所有实验室用于蛋白尿分型。对 161 份尿液进行了白蛋白尿和尿 IgG 检测。以专家中心读取的尿电泳结果为参照方法,绘制了 ROC 曲线。使用的判定阈值是:肾小球性蛋白尿的定义是白蛋白+IgG 蛋白比率大于 75.4%(特异性 100%),肾小管性或超负荷蛋白尿的定义是白蛋白比率小于 37.3%(灵敏度 100%)。所选算法的结果与我们研究中使用的参考方法之间的一致性为 88%,卡帕值为 0.807(95% CI [0.729 至 0.885])。该算法的表现表明,尽管其适应症有限,但仍可在临床重大蛋白尿的诊断策略中占有一席之地。应由每位生物学家根据临床医生的招聘、习惯和需求来评估该算法的价值。
{"title":"[Evaluation of an algorithm based on quantitative assays of glomerular parameters (albuminuria and urinary IgG) for proteinuria typing].","authors":"Ihsane Benlyamani, Nathalie Rousseau, Christine Lombard, Emmanuel Villar, Matthieu Pecquet","doi":"10.1684/abc.2024.1887","DOIUrl":"10.1684/abc.2024.1887","url":null,"abstract":"<p><p>The first orientation test for proteinuria typing is electrophoresis. However, this technique has several drawbacks, such as delayed turnaround time and subjective readings. Some laboratories therefore use quantitative assays of glomerular markers combined with tubular markers. However, the cost of reagents and the instability of certain markers are significant drawbacks for some peripheral laboratories. The aim of this study is to evaluate the implementation of an algorithm based on parameters that can be used by all laboratories for proteinuria typing within a timeframe compatible with the urgency of the situation. Albuminuria and urinary IgG were determined on 161 urines. ROC curves were produced, using urine electrophoresis read by an expert center as the reference method. The decision thresholds used are: glomerular proteinuria is defined by a Albumin+IgGproteinsratio greater than 75.4% (100% specificity), and tubular or overload proteinuria is defined by by a Albuminproteinsratio less than 37.3% (100% sensitivity). Agreement between the results of the algorithm selected and the reference method used in our study was 88 %, with a kappa value of 0.807 (95% CI [0.729 to 0.885]). The algorithm's performance suggests that it can find its place in the diagnostic strategy for clinically significant proteinuria, despite its limited indications. It is up to each biologist to assess the value of this algorithm in relation to the recruitment, habits and needs of clinicians.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 2","pages":"201-213"},"PeriodicalIF":0.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140892177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Artificial intelligence: to a better predictive strategy for testicular sperm extraction outcome in azoospermia]. [人工智能:为无精症患者的睾丸取精结果提供更好的预测策略]。
Pub Date : 2024-06-05 DOI: 10.1684/abc.2024.1882
Guillaume Bachelot, Anna Ly, Diane Rivet-Danon, Nathalie Sermondade, Valentine Frydman, Antonin Lamazière, Rahaf Haj Hamid, Rachel Levy, Charlotte Dupont

Azoospermia, defined as the absence of sperm in the semen, is found in 10-15 % of infertile patients. Two-thirds of these cases are caused by impaired spermatogenesis, known as non-obstructive azoospermia (NOA). In this context, surgical sperm extraction using testicular sperm extraction (TESE) is the best option and can be offered to patients as part of fertility preservation, or to benefit from in vitro fertilization. The aim of the preoperative assessment is to identify the cause of NOA and evaluate the status of spermatogenesis. Its capacity to predict TESE success remains limited. As a result, no objective and reliable criteria are currently available to guide professionals on the chances of success and enable them to correctly assess the benefit-risk balance of this procedure. Artificial intelligence (AI), a field of research that has been rapidly expanding in recent years, has the potential to revolutionize medicine by making it more predictive and personalized. The aim of this review is to introduce AI and its key concepts, and then to examine the current state of research into predicting the success of TESE.

无精子症是指精液中没有精子,在不育患者中占 10-15% 的比例。其中三分之二的病例是由精子生成障碍引起的,即非梗阻性无精子症(NOA)。在这种情况下,使用睾丸取精术(TESE)进行手术取精是最好的选择,患者可将其作为生育力保存的一部分,或从体外受精中获益。术前评估的目的是确定无精子症的原因并评估精子发生的状况。但其预测 TESE 成功率的能力仍然有限。因此,目前还没有客观可靠的标准来指导专业人员确定成功的几率,并使他们能够正确评估该手术的效益与风险平衡。人工智能(AI)是近年来迅速发展起来的一个研究领域,它有可能使医学更具预测性和个性化,从而彻底改变医学。本综述旨在介绍人工智能及其关键概念,然后探讨预测 TESE 成功率的研究现状。
{"title":"[Artificial intelligence: to a better predictive strategy for testicular sperm extraction outcome in azoospermia].","authors":"Guillaume Bachelot, Anna Ly, Diane Rivet-Danon, Nathalie Sermondade, Valentine Frydman, Antonin Lamazière, Rahaf Haj Hamid, Rachel Levy, Charlotte Dupont","doi":"10.1684/abc.2024.1882","DOIUrl":"10.1684/abc.2024.1882","url":null,"abstract":"<p><p>Azoospermia, defined as the absence of sperm in the semen, is found in 10-15 % of infertile patients. Two-thirds of these cases are caused by impaired spermatogenesis, known as non-obstructive azoospermia (NOA). In this context, surgical sperm extraction using testicular sperm extraction (TESE) is the best option and can be offered to patients as part of fertility preservation, or to benefit from in vitro fertilization. The aim of the preoperative assessment is to identify the cause of NOA and evaluate the status of spermatogenesis. Its capacity to predict TESE success remains limited. As a result, no objective and reliable criteria are currently available to guide professionals on the chances of success and enable them to correctly assess the benefit-risk balance of this procedure. Artificial intelligence (AI), a field of research that has been rapidly expanding in recent years, has the potential to revolutionize medicine by making it more predictive and personalized. The aim of this review is to introduce AI and its key concepts, and then to examine the current state of research into predicting the success of TESE.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 2","pages":"139-149"},"PeriodicalIF":0.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140873775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LncRNA RP11-773H22.4 is upregulated in severe pneumonia and may be a diagnostic and prognostic marker for severe pneumonia. LncRNA RP11-773H22.4 在重症肺炎中上调,可能是重症肺炎的诊断和预后标志物。
Pub Date : 2024-06-05 DOI: 10.1684/abc.2024.1886
Yan Cao, Feiyan Wang

The incidence of pneumonia has become increasingly prevalent, and its severity has been continuously escalating, bringing significant damage and stress to people's lives. The regulatory role of RP11-773H22.4 in the onset and development of severe pneumonia is emerging as an important factor, however, the exact mechanisms controlling its effects have not been fully elucidated. ROC curve and Kaplan-Meier curve were employed to assess the diagnostic and prognostic significance of RP11-773H22.4 in severe pneumonia. qRT-PCR was employed to assess the RP11-773H22.4 and miR-1287-5p expression. The CCK-8 was employed to assess cell viability. The rate of apoptosis was measured utilizing flow cytometric. The concentration of inflammatory factors was detected by ELISA kit. The interaction between RP11-773H22.4 and miR-1287-5p was verified by dual luciferase reporter gene assay. In individuals afflicted with severe pneumonia, there was an observed up-regulation in RP11-773H22.4 expression and a corresponding decline in miR-1287-5p expression. RP11-773H22.4 demonstrated diagnostic and prognostic significance for severe pneumonia. RP11-773H22.4 augmented the viability of MRC-5 cells with LPS treatment by modulating miR-1287-5p, leading to a reduction in apoptosis and lower levels of inflammatory cytokines. RP11-773H22.4 was highly expressed in severe pneumonia and may serve as a diagnostic and prognostic marker for severe pneumonia. miR-1287-5p was downregulated in severe pneumonia, and RP11-773H22.4 participated in the pathogenesis of severe pneumonia by regulating the expression of miR-1287-5p.

肺炎的发病率越来越高,其严重程度也不断升级,给人们的生活带来了巨大的伤害和压力。RP11-773H22.4在重症肺炎发病和发展过程中的调控作用正逐渐成为一个重要因素,但其确切的作用机制尚未完全阐明。研究采用 ROC 曲线和 Kaplan-Meier 曲线评估 RP11-773H22.4 在重症肺炎中的诊断和预后意义。采用 CCK-8 评估细胞活力。利用流式细胞仪测量细胞凋亡率。用 ELISA 试剂盒检测炎症因子的浓度。RP11-773H22.4和miR-1287-5p之间的相互作用通过双荧光素酶报告基因测定得到了验证。在重症肺炎患者中,观察到 RP11-773H22.4 表达上调,miR-1287-5p 表达相应下降。RP11-773H22.4 对重症肺炎具有诊断和预后意义。通过调节 miR-1287-5p,RP11-773H22.4 提高了经 LPS 处理的 MRC-5 细胞的活力,导致细胞凋亡减少和炎症细胞因子水平降低。RP11-773H22.4在重症肺炎中高表达,可作为重症肺炎的诊断和预后标志物;miR-1287-5p在重症肺炎中下调,RP11-773H22.4通过调节miR-1287-5p的表达参与了重症肺炎的发病机制。
{"title":"LncRNA RP11-773H22.4 is upregulated in severe pneumonia and may be a diagnostic and prognostic marker for severe pneumonia.","authors":"Yan Cao, Feiyan Wang","doi":"10.1684/abc.2024.1886","DOIUrl":"10.1684/abc.2024.1886","url":null,"abstract":"<p><p>The incidence of pneumonia has become increasingly prevalent, and its severity has been continuously escalating, bringing significant damage and stress to people's lives. The regulatory role of RP11-773H22.4 in the onset and development of severe pneumonia is emerging as an important factor, however, the exact mechanisms controlling its effects have not been fully elucidated. ROC curve and Kaplan-Meier curve were employed to assess the diagnostic and prognostic significance of RP11-773H22.4 in severe pneumonia. qRT-PCR was employed to assess the RP11-773H22.4 and miR-1287-5p expression. The CCK-8 was employed to assess cell viability. The rate of apoptosis was measured utilizing flow cytometric. The concentration of inflammatory factors was detected by ELISA kit. The interaction between RP11-773H22.4 and miR-1287-5p was verified by dual luciferase reporter gene assay. In individuals afflicted with severe pneumonia, there was an observed up-regulation in RP11-773H22.4 expression and a corresponding decline in miR-1287-5p expression. RP11-773H22.4 demonstrated diagnostic and prognostic significance for severe pneumonia. RP11-773H22.4 augmented the viability of MRC-5 cells with LPS treatment by modulating miR-1287-5p, leading to a reduction in apoptosis and lower levels of inflammatory cytokines. RP11-773H22.4 was highly expressed in severe pneumonia and may serve as a diagnostic and prognostic marker for severe pneumonia. miR-1287-5p was downregulated in severe pneumonia, and RP11-773H22.4 participated in the pathogenesis of severe pneumonia by regulating the expression of miR-1287-5p.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 2","pages":"187-199"},"PeriodicalIF":0.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140871702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Toxicology of synthetic cannabinoids]. [合成大麻素的毒理学]。
Pub Date : 2024-06-05 DOI: 10.1684/abc.2024.1888
Youssef Mouraouakkil, Radia Mounir, Mina Ait El Cadi, Jamal Lamsaouri, Yassir Bousliman, Rachid ElJaoudi

Synthetic cannabinoids (CS), or synthetic endocannabinoid receptor agonists, were initially synthesized for basic research into exocannabinoid signaling pathways, as well as in clinical research for their analgesic properties. The use of CS for recreational purposes is a recent phenomenon, but one that has grown very quickly in recent years, since these molecules now represent the main category of new synthetic products (NPS). This literature review aims to bring together current data regarding the use and effects caused by CS in humans. The relationship between the structure and activity of these CSs, the pharmacology and adverse effects of these CSs and finally the different methods of analyzing CSs. A better understanding of this phenomenon is essential to raise awareness among stakeholders in the health field.

合成大麻素(CS)或合成内源性大麻素受体激动剂最初是为了对外源大麻素信号通路进行基础研究而合成的,在临床研究中也是为了获得其镇痛特性。将 CS 用于娱乐目的是最近才出现的现象,但近年来发展非常迅速,因为这些分子现已成为新合成产品(NPS)的主要类别。本文献综述旨在汇集有关 CS 的使用及其对人体影响的最新数据。这些 CS 的结构和活性之间的关系、这些 CS 的药理学和不良反应,以及分析 CS 的不同方法。更好地了解这一现象对于提高健康领域利益相关者的认识至关重要。
{"title":"[Toxicology of synthetic cannabinoids].","authors":"Youssef Mouraouakkil, Radia Mounir, Mina Ait El Cadi, Jamal Lamsaouri, Yassir Bousliman, Rachid ElJaoudi","doi":"10.1684/abc.2024.1888","DOIUrl":"10.1684/abc.2024.1888","url":null,"abstract":"<p><p>Synthetic cannabinoids (CS), or synthetic endocannabinoid receptor agonists, were initially synthesized for basic research into exocannabinoid signaling pathways, as well as in clinical research for their analgesic properties. The use of CS for recreational purposes is a recent phenomenon, but one that has grown very quickly in recent years, since these molecules now represent the main category of new synthetic products (NPS). This literature review aims to bring together current data regarding the use and effects caused by CS in humans. The relationship between the structure and activity of these CSs, the pharmacology and adverse effects of these CSs and finally the different methods of analyzing CSs. A better understanding of this phenomenon is essential to raise awareness among stakeholders in the health field.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 2","pages":"151-173"},"PeriodicalIF":0.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140892268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Professor Philippe Gillery honoured at WorldLab Dubai (UAE) with the IFCC Howard Morris 2024 Prize]. [Philippe Gillery 教授在迪拜世界实验室(阿联酋)荣获 IFCC 霍华德-莫里斯 2024 奖]。
Pub Date : 2024-06-01 DOI: 10.1684/abc.2024.1894
Bernard Gouget, Katell Peoc'h
{"title":"[Professor Philippe Gillery honoured at WorldLab Dubai (UAE) with the IFCC Howard Morris 2024 Prize].","authors":"Bernard Gouget, Katell Peoc'h","doi":"10.1684/abc.2024.1894","DOIUrl":"https://doi.org/10.1684/abc.2024.1894","url":null,"abstract":"","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 3","pages":"249-251"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Dr David Barthelemy, winner of the IFCC Gérard Siest Prize awarded at the WorldLab Congress, Dubai 2024]. [David Barthelemy 博士,在 2024 年迪拜世界实验室大会上荣获国际化学理事会热拉尔-西斯特奖]。
Pub Date : 2024-06-01 DOI: 10.1684/abc.2024.1901
Bernard Gouget, Delphine Collin-Chavagnac, Katell Peoc'h
{"title":"[Dr David Barthelemy, winner of the IFCC Gérard Siest Prize awarded at the WorldLab Congress, Dubai 2024].","authors":"Bernard Gouget, Delphine Collin-Chavagnac, Katell Peoc'h","doi":"10.1684/abc.2024.1901","DOIUrl":"https://doi.org/10.1684/abc.2024.1901","url":null,"abstract":"","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 3","pages":"252-253"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Evaluation of a new portable analyzer, HemoCue® Hb801, for hemoglobin point-of-care testing]. [评估用于血红蛋白床旁检测的新型便携式分析仪 HemoCue® Hb801]。
Pub Date : 2024-04-19 DOI: 10.1684/abc.2024.1868
Bryan Zamorano, Yolla Sakr, Frédérique Galopin-Dubois

The use of portable hemoglobin measuring devices is widespread. In this context, the company HemoCue® has put on the market a new device, the Hb801. It uses a whole blood absorbance measurement method and not the azidmethemoglobin measurement method used by HemoCue's older devices. We evaluated this new equipment on EDTA venous blood. Hb801 is lightweight, compact, requires a volume of 10 μL of blood and renders its result in less than a second. The repeatability and intermediate precision are close to the values expected according to Ricos, with coefficients of variation respectively for a low level of hemoglobin: 2.1% and 1.9%, for an average level: 0.8% and 1.5% and for a high level: 1.5% and 1.3%. Comparison to our laboratory reference method (XN-10 Sysmex®) and HemoCue® Hb201+ was performed on 96 samples. Bias (SD) found were: XN-10: +0.42 g/dL (0.17), HemoCue® Hb201+: +0.17 g/dL (0.41). Clinically acceptable performance (within ± 1 g/dL of reference hemoglobin) was high: 93.8%. In the end, this device seems to us to be suitable for hemoglobin point-of-care testing.

便携式血红蛋白测量仪的使用非常普遍。在这种情况下,HemoCue® 公司向市场推出了一款新设备 Hb801。它采用的是全血吸光度测量方法,而不是 HemoCue 旧设备使用的叠氮血红蛋白测量方法。我们对这种新设备进行了 EDTA 静脉血评估。Hb801 重量轻,结构紧凑,只需 10 μL 的血量,并能在一秒钟内得出结果。重复性和中间精度接近 Ricos 的预期值,低水平血红蛋白的变异系数分别为 2.1% 和 1.9%,平均水平为 0.8% 和 1.5%,高水平为 1.5% 和 1.3%。对 96 份样本进行了与实验室参考方法(XN-10 Sysmex®)和 HemoCue® Hb201+ 的比较。发现的偏差(SD)如下XN-10: +0.42 g/dL (0.17), HemoCue® Hb201+:+0.17 g/dL (0.41)。临床可接受的性能(参考血红蛋白在 ± 1 g/dL 以内)高达 93.8%。最后,我们认为该设备适用于血红蛋白的床旁检测。
{"title":"[Evaluation of a new portable analyzer, HemoCue<sup>®</sup> Hb801, for hemoglobin point-of-care testing].","authors":"Bryan Zamorano, Yolla Sakr, Frédérique Galopin-Dubois","doi":"10.1684/abc.2024.1868","DOIUrl":"https://doi.org/10.1684/abc.2024.1868","url":null,"abstract":"<p><p>The use of portable hemoglobin measuring devices is widespread. In this context, the company HemoCue® has put on the market a new device, the Hb801. It uses a whole blood absorbance measurement method and not the azidmethemoglobin measurement method used by HemoCue's older devices. We evaluated this new equipment on EDTA venous blood. Hb801 is lightweight, compact, requires a volume of 10 μL of blood and renders its result in less than a second. The repeatability and intermediate precision are close to the values expected according to Ricos, with coefficients of variation respectively for a low level of hemoglobin: 2.1% and 1.9%, for an average level: 0.8% and 1.5% and for a high level: 1.5% and 1.3%. Comparison to our laboratory reference method (XN-10 Sysmex®) and HemoCue® Hb201+ was performed on 96 samples. Bias (SD) found were: XN-10: +0.42 g/dL (0.17), HemoCue® Hb201+: +0.17 g/dL (0.41). Clinically acceptable performance (within ± 1 g/dL of reference hemoglobin) was high: 93.8%. In the end, this device seems to us to be suitable for hemoglobin point-of-care testing.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 1","pages":"103-111"},"PeriodicalIF":0.0,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Programmed cell death in autoimmune diseases: ferroptosis. 自身免疫性疾病中的程序性细胞死亡:铁变态反应。
Pub Date : 2024-04-19 DOI: 10.1684/abc.2024.1866
Jiantao Sun, Lujuan Huang, Jiawei Wang, Yelang Hu, Wenmin Wang, Haihong Zhu

Ferroptosis is an iron dependent cell death driven by lipid peroxidation. Over the past decade, increasing evidence has confirmed that ferroptosis plays an irreplaceable role in the occurrence and development of many diseases, including various cancers, neurodegenerative diseases, cardiovascular diseases and autoimmune diseases. Autoimmune disease is an inflammatory disease characterized by the breakdown of immune tolerance. Nowadays, accumulating evidence indicates that ferroptosis is closely related to the pathogenesis of autoimmune diseases. Therefore, this review briefly introduced the mechanism of ferroptosis, and focused on the related research of ferroptosis in multiple autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), ankylosing spondylitis (AS). In addition, we also presented the idea of targeting ferroptosis as a potential therapeutic target for patients with autoimmune diseases, which may provide a direction for the development of new therapeutic strategies.

铁中毒是一种由脂质过氧化驱动的铁依赖性细胞死亡。在过去十年中,越来越多的证据证实,铁变态反应在许多疾病的发生和发展中起着不可替代的作用,包括各种癌症、神经退行性疾病、心血管疾病和自身免疫性疾病。自身免疫性疾病是一种以免疫耐受破坏为特征的炎症性疾病。目前,越来越多的证据表明,铁蛋白沉积与自身免疫性疾病的发病机制密切相关。因此,这篇综述简要介绍了铁蛋白沉积的机制,并重点探讨了铁蛋白沉积在系统性红斑狼疮(SLE)、类风湿性关节炎(RA)、多发性硬化症(MS)、强直性脊柱炎(AS)等多种自身免疫性疾病中的相关研究。此外,我们还提出了针对自身免疫性疾病患者的潜在治疗靶点--铁蛋白沉积的观点,这可能为开发新的治疗策略提供了一个方向。
{"title":"Programmed cell death in autoimmune diseases: ferroptosis.","authors":"Jiantao Sun, Lujuan Huang, Jiawei Wang, Yelang Hu, Wenmin Wang, Haihong Zhu","doi":"10.1684/abc.2024.1866","DOIUrl":"https://doi.org/10.1684/abc.2024.1866","url":null,"abstract":"<p><p>Ferroptosis is an iron dependent cell death driven by lipid peroxidation. Over the past decade, increasing evidence has confirmed that ferroptosis plays an irreplaceable role in the occurrence and development of many diseases, including various cancers, neurodegenerative diseases, cardiovascular diseases and autoimmune diseases. Autoimmune disease is an inflammatory disease characterized by the breakdown of immune tolerance. Nowadays, accumulating evidence indicates that ferroptosis is closely related to the pathogenesis of autoimmune diseases. Therefore, this review briefly introduced the mechanism of ferroptosis, and focused on the related research of ferroptosis in multiple autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), ankylosing spondylitis (AS). In addition, we also presented the idea of targeting ferroptosis as a potential therapeutic target for patients with autoimmune diseases, which may provide a direction for the development of new therapeutic strategies.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 1","pages":"33-42"},"PeriodicalIF":0.0,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140868395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[2024, a year of openness]. [2024 年,开放之年]。
Pub Date : 2024-04-19 DOI: 10.1684/abc.2024.1872
Katell Peoc'h
{"title":"[2024, a year of openness].","authors":"Katell Peoc'h","doi":"10.1684/abc.2024.1872","DOIUrl":"https://doi.org/10.1684/abc.2024.1872","url":null,"abstract":"","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 1","pages":"5-6"},"PeriodicalIF":0.0,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140864751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Hormone anti-müllérienne (AMH) en pédiatrie : établissement de valeurs de référence avec le dosage de l'AMH Fujirebio® Lumipulse G et comparaison avec le dosage Roche® Elecsys sur les mêmes échantillons pédiatriques]. [儿科抗苗勒氏管激素 (AMH):用富士比奥® Lumipulse G AMH 检测法确定参考值,并在相同儿科样本上与罗氏® Elecsys 检测法进行比较]。
Pub Date : 2024-04-19 DOI: 10.1684/abc.2024.1867
Jean-Baptiste Delaye, Olivier Le Tilly, Emmanuel Enard, Christine Collet, Patrick Emond, Diane Dufour-Rainfray

We performed a method comparison between the Fujirebio® Lumipulse G AMH assay and the Roche® Elecsys AMH assay using the same pediatric samples. We described full pediatric gender and age-specific reference ranges for AMH using the Fujirebio® AMH assay on the Lumipulse G 600 II. The study was performed on 281 plasma samples collected in tubes with lithium heparin. The samples were from patients (135 males and 146 females) aged from 3 days to 22 years collected at the University Hospital Center of Tours. The Fujirebio® Lumipulse method showed excellent correlation with Roche® Elecsys but had a significant proportional positive bias. The data were used to propose pediatric reference values adapted to the Fujirebio® method. Our study described full pediatric gender and age-related reference ranges for AMH using the Fujirebio® AMH assay on the Lumipulse G600II. The delineation between normal male and female AMH concentrations make them valuable clinical tools for the monitoring of pediatric sexual and reproductive development from early childhood through the pubertal transition into adulthood.

我们使用相同的儿科样本对Fujirebio® Lumipulse G AMH测定和Roche® Elecsys AMH测定进行了方法比较。我们描述了在Lumipulse G 600 II上使用Fujirebio® AMH测定法检测AMH的全部儿科性别和年龄特异性参考范围。这项研究是在用肝素锂试管采集的 281 份血浆样本中进行的。样本来自图尔大学医院中心采集的 3 天至 22 岁的患者(男性 135 人,女性 146 人)。Fujirebio® Lumipulse 方法与 Roche® Elecsys 方法的相关性极佳,但存在明显的正比例偏差。我们利用这些数据提出了适用于富士比奥®方法的儿科参考值。我们的研究描述了在Lumipulse G600II上使用Fujirebio® AMH检测法检测AMH的全部儿科性别和年龄相关参考范围。正常男性和女性AMH浓度之间的界限使其成为有价值的临床工具,用于监测小儿从幼儿期到青春期过渡到成年期的性发育和生殖发育情况。
{"title":"[Hormone anti-müllérienne (AMH) en pédiatrie : établissement de valeurs de référence avec le dosage de l'AMH Fujirebio<sup>®</sup> Lumipulse G et comparaison avec le dosage Roche<sup>®</sup> Elecsys sur les mêmes échantillons pédiatriques].","authors":"Jean-Baptiste Delaye, Olivier Le Tilly, Emmanuel Enard, Christine Collet, Patrick Emond, Diane Dufour-Rainfray","doi":"10.1684/abc.2024.1867","DOIUrl":"https://doi.org/10.1684/abc.2024.1867","url":null,"abstract":"<p><p>We performed a method comparison between the Fujirebio® Lumipulse G AMH assay and the Roche® Elecsys AMH assay using the same pediatric samples. We described full pediatric gender and age-specific reference ranges for AMH using the Fujirebio® AMH assay on the Lumipulse G 600 II. The study was performed on 281 plasma samples collected in tubes with lithium heparin. The samples were from patients (135 males and 146 females) aged from 3 days to 22 years collected at the University Hospital Center of Tours. The Fujirebio® Lumipulse method showed excellent correlation with Roche® Elecsys but had a significant proportional positive bias. The data were used to propose pediatric reference values adapted to the Fujirebio® method. Our study described full pediatric gender and age-related reference ranges for AMH using the Fujirebio® AMH assay on the Lumipulse G600II. The delineation between normal male and female AMH concentrations make them valuable clinical tools for the monitoring of pediatric sexual and reproductive development from early childhood through the pubertal transition into adulthood.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 1","pages":"59-69"},"PeriodicalIF":0.0,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140864752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Annales de biologie clinique
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1